美股市場個股詳情
KZIA Kazia Therapeutics
- 0.282
- +0.007+2.47%
收盤價 05/21 16:00 (美東)
- 0.282
- 0.000-0.04%
盤後 18:48 (美東)
742.87萬總市值-757市盈率TTM
0.287最高價0.236最低價4.58萬股成交量0.275今開0.275昨收1.17萬成交額0.19%換手率虧損市盈率(靜)2636.15萬總股本1.34052周最高2.12市淨率668.50萬流通值0.18752周最低--股息TTM2372.23萬流通股15.850歷史最高--股息率TTM18.79%振幅0.187歷史最低0.256平均價1股每手
Kazia Therapeutics股票討論區
登錄發表評論
$Kazia Therapeutics(KZIA.US$ SYDNEY, May 1, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce that the Safety Review Team (SRT) of the EVT801 Phase 1 clinical trial has concluded that the primary and secondary objectives of stage 1 of the trial have successfully been met. It shoulda been a weight loss drug making good advancement! It would be climbing then! Hehehe![]()
3
9
$Kazia Therapeutics(KZIA.US$ Kazia Therapeutics Ltd - Pursuant to Purchase Agreement, May Sell to Alumni Capital up to $15 Mln of American Depositary Shares From Time to Time
1
Taking a look at $Kazia Therapeutics(KZIA.US$
Here's a look at the current concensus:
Reasons to consider adding this to your portfolio:
What is the Fibonacci indicating?
Short Interest:
Remember to pay attention to the Moving Average (MA) and Volume-weighted average price (VWAP) before hoping on board!
Good Luck and Happy Trading!
Here's a look at the current concensus:
Reasons to consider adding this to your portfolio:
What is the Fibonacci indicating?
Short Interest:
Remember to pay attention to the Moving Average (MA) and Volume-weighted average price (VWAP) before hoping on board!
Good Luck and Happy Trading!
+8
$Kazia Therapeutics(KZIA.US$ Kazia Therapeutics Licenses Paxalisib To Sovargen For Intractable Seizures In Rare Central Nervous System Diseases
1
3
$Annovis Bio(ANVS.US$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$迪卡斯(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$迪卡斯(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
10
1
In the world of biotechnology, every new development is a potential game changer, and the recent announcement by Kazia Therapeutics Limited ($KZIA) certainly fits the bill. The company has reported an early conclusion of their clinical trial after successfully reaching the primary endpoint. But what does this mean for you, the reader? Let's delve into it.
https://stockregion.app/p/therapeutics-company-reports-early
https://stockregion.app/p/therapeutics-company-reports-early
1
$Kazia Therapeutics(KZIA.US$ 利好都扶不起來 真是浪費我的時間
已翻譯
1
1
$Kazia Therapeutics(KZIA.US$ Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
3 MINUTES AGO, 7:30 AM EST
VIA PR NEWSWIRE
3 MINUTES AGO, 7:30 AM EST
VIA PR NEWSWIRE
3
2
Kazia's CEO, Dr. John Friend, expressed delight at the appointments, stating that Apple's deep biopharmaceutical leadership experience across finance, business development, and commercial operations will be extremely valuable for the company as it enters its next phase of growth.
暫無評論
分析
目標價預測
暫無數據
熱議
美股
綜合熱度
股票代碼
最新價
漲跌幅
Jaguar8 : 因為它是超重問題，因此可能會稍後攀升
Stock_Drift : 我來了
謝謝
Trytosaveabit樓主 Stock_Drift: 歡迎您 GL
Mod Tan : 他們只是發行招股章程，再次稀釋股份。
Trytosaveabit樓主 Mod Tan: 這是對於 2 月提交的修正案！可能沒有很大的影響？需要完成更新的價格/金額！GL
查看更多評論...